Cerus (CERS) vs Delcath Systems (DCTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cerus (CERS) has outperformed Delcath Systems (DCTH) over the past year, gaining 43.1% versus a gain of 35.5%. Over five years, DCTH leads with a +59.8% price change compared with -62.6% for CERS. Delcath Systems is the larger company by market cap ($525.5 million vs $463.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERS | DCTH |
|---|---|---|
| Share price | $2.30 | $15.15 |
| Market cap | $463.51M | $525.51M |
| 1-day change | +0.88% | +0.70% |
| YTD return | +11.17% | +48.91% |
| 1-year return | +43.13% | +35.50% |
| 5-year return | -62.58% | +59.83% |
| Forward P/E | — | 336.56 |
| EPS (TTM) | $-0.03 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.47 | $17.42 |
| 52-week low | $1.38 | $8.12 |
| Distance from 52-week high | -33.72% | -13.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +123.04% | +58.47% |
| Average volume | 2.15M | 479.73K |
| Shares outstanding | 201.52M | 34.70M |
| Employees | 261 | 156 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Health Care · Medical/Dental Instruments · 261 employees
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
CERS vs DCTH FAQ
Which is bigger, Cerus or Delcath Systems?
Delcath Systems (DCTH) is larger, with a market capitalization of $525.51M compared with $463.51M for Cerus (CERS).
Which stock has performed better over the past year, CERS or DCTH?
CERS returned +43.13% over the past 12 months, compared with +35.50% for DCTH (price return, excluding dividends). Past performance does not predict future results.
Are Cerus and Delcath Systems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.